Updated on 21 February 2014
Medical Innovation Ventures, a university spin off company, is an example of local grown IVD companies with ambitious national and regional plans. Incidentally, the company has also received recognition from the government as the organization that will lay the foundation towards up scaling the IVD sector in the country. The company offers accurate, fast, affordable, and simple-to-use diagnostic solutions including point-of-Care tests and molecular diagnostic kits. Current focus of the company includes infectious diseases that are important for emerging economies where simple, accurate and stable diagnostic tests are unavailable or inaccessible to those who need them. Its platform enables just-in-time development of diagnostic tests for any pathogens detectable by immunoassays. The kits are based on a proprietary thermostable technology, which makes storage and transportation of these products convenient and helps to avoid costs related to cold-chain requirements of conventional products. Another proprietary platform of the company is a lateral flow technology that enables the detection of DNA amplification results in about 10 minutes, compared to the conventional methods which takes about an hour and involves carcinogenic chemicals.
As the company spearheading EPP7 for Malaysia, Mediven is also actively seeking to harness the economic potential of the IVD industry by playing a critical role in bridging the gap between academia and industry. By initiating strategic public-private partnerships with Malaysian R&D institutions, Mediven targets to tap the commercial potential of locally developed technologies. Addressing the needs of developing nations by improving diagnostics of neglected tropical diseases (NTDs) is another target of the company, and has already developed a number of products intended for this.
Geneflux Bioscience is another promising IVD company in Malaysia involved in the development and manufacturing of molecular diagnostic kits and providing diagnostic services. Products and services of the company cover a range of areas including tests based on nucleic acid, microbiology, ELISA, and rapid antigen tests. The company has received numerous national and regional recognitions. The most recent is the "Biomedical Excellence Award 2013" in October 2013 from the Ministry of Science, Technology, and Innovation (MOSTI) and Malaysian Biotechnology Corporation. Geneflux is also a recipient of two regional awards in the molecular diagnostics segment from Frost & Sullivan in 2010 as well as in 2012.
Other Malaysia-based companies that may play key roles in helping the country to achieve its goals in diagnostics sector by 2020 include DNA LAB, Venture Technologies, Malaysia BioDiagnostics Research (MBDr), Infovalley Life Sciences, and GeneNews Diagnostics. Together, these companies offer diagnostic products targeting a wide range of diseases, including infectious diseases, genetic disorders, and cancer. This indicates the potential of Malaysia to emerge as a key provider of affordable diagnostic solutions in the region.